Welsh technology company, Ceryx Medical has announced a first patient enrollment in the RSA-Pace multi-centre study. The study aims to evaluate the safety of the Cysoni™ RSA Pacemaker temporary pacing technology in post-surgical heart failure patients who require temporary pacing. The RSA-Pace study will unroll up to 60 patients at centers in the UK, New Zealand and Australia. The first patient was treated at Waikato Hospital in Hamilton, New Zealand.
Background
Our readers will know that they can search specialities including the word cardio directly on our pages. Ceryx Medical is a new addition to the roster of medical device technology companies we’ve covered over the years.
Founded in 2016, Ceryx Medical specialises in developing bioelectronic devices that emulate the body’s natural processes to treat chronic conditions such as heart failure.
Temporary Pacing
Clinicians will insert a temporary pacing wire in patients for whom they consider a slow heartbeat is likely to recover on its own or if treatment is required urgently. They may also apply it in a post-surgical setting. This can include restoring the natural synchronisation between the heart and lungs. Clinicians term this Respiratory Sinus Arrhythmia (RSA). Ceryx Medical’s Cysoni™ aims to enhance cardiac function and in so doing improve patient outcomes.
Investigator comments
Dr Martin Stiles, Principle Investigator at Waikato Hospital.
“We are delighted to have enrolled the first patient in this important study. The Ceryx Cysoni pre-clinical results have been most impressive and have shown that this technology has the potential to improve cardiac output compared to existing pacing technologies. This is an exciting and novel approach, and we are interested to understand the benefits of RSA pacing in a post-surgical patient population” said
Company comments
“We would like to thank Dr Stiles and the team at Waikato” said Dr Stuart Plant CEO, Ceryx.
“The results from this first in human study will help us understand the role of RSA pacing as we strive to develop temporary and permanent pacing devices based on this unique technology. We are exceptionally pleased with the performance of the Cysoni system so far. Indeed its ability to restore RSA appears to be exceeding our expectations.”
Source: Life Science Newswire
published: December 9, 2024 in: News
